Tilray Brands (NASDAQ:TLRY) Shares Down 2% – Here’s What Happened

Tilray Brands, Inc. (NASDAQ:TLRY) dropped 2% during trading on Tuesday . The company traded as low as $7.17 and last traded at $7.20. Approximately 2,521,470 shares changed hands during mid-day trading, a decline of 38% from the average daily volume of 4,054,649 shares. The stock had previously closed at $7.35.

Tilray Brands News Roundup

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Acquired BrewDog’s Australian brewing and bar assets, giving Tilray a profitable operating base in Australia and a platform to scale BrewDog and other beverage SKUs across APAC — expands the company’s consumer-products footprint and retail/grocery distribution opportunities. Tilray Brands Acquires BrewDog Australia
• Positive Sentiment: Earlier deals (UK BrewDog assets and a partnership with Carlsberg) continue to build an international beverage platform — management forecasts material revenue from these moves, which could diversify revenue away from cannabis and improve gross margins if integrations go well. Tilray Brands Expands Beer And Cannabis Footprint With Carlsberg Deal
• Neutral Sentiment: Company guidance/targets: management and coverage note ambitions for meaningful revenue growth (company commentary and coverage cite ~$1.2B revenue next year and BrewDog contributing ~ $200M by FY2027) — growth is meaningful if delivered but is largely acquisition-driven. Tilray Brands Expects to Generate $1.2 Billion in Revenue Next Year
• Neutral Sentiment: Macro/sector note: coverage of Canadian cannabis stocks highlights ongoing industry evolution and opportunity as legalization expands globally — this context supports long-term demand but does not remove near-term execution risk. Canadian Cannabis Stocks to Watch in March 2026
• Negative Sentiment: Investor skepticism and sell-side caution: some analysts view Tilray as a longer-term story but rate it a “hold” now due to execution, integration and near-term profitability uncertainty — that debate is pressuring the stock as buyers wait for proof. Tilray’s Going To Be Great, But For Now It’s A Hold
• Negative Sentiment: Ongoing financial risks: despite revenue growth, Tilray still reports negative margins and analysts model negative EPS for the year — heavy M&A raises integration, execution and potential dilution risks that can weigh on the share price until profitability improves. Tilray’s BrewDog Australia Deal Expands Beverage Reach And Investor Debate

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TLRY. Canaccord Genuity Group assumed coverage on shares of Tilray Brands in a research report on Tuesday, January 27th. They set a “hold” rating for the company. Zacks Research upgraded shares of Tilray Brands from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 11th. Wall Street Zen downgraded shares of Tilray Brands from a “hold” rating to a “sell” rating in a report on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tilray Brands in a research report on Wednesday, January 21st. Finally, Roth Mkm decreased their price objective on shares of Tilray Brands from $20.00 to $10.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 20th. One investment analyst has rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $13.33.

Tilray Brands Trading Down 2.0%

The firm has a 50-day moving average of $8.25 and a two-hundred day moving average of $10.93. The firm has a market capitalization of $838.87 million, a P/E ratio of -0.33 and a beta of 1.95. The company has a current ratio of 2.81, a quick ratio of 1.72 and a debt-to-equity ratio of 0.19.

Tilray Brands (NASDAQ:TLRY) last released its earnings results on Thursday, January 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.12. The firm had revenue of $217.51 million for the quarter, compared to analysts’ expectations of $211.15 million. Tilray Brands had a negative return on equity of 6.35% and a negative net margin of 251.69%.During the same quarter in the previous year, the business posted ($0.03) earnings per share. On average, analysts anticipate that Tilray Brands, Inc. will post -0.2 EPS for the current year.

Institutional Trading of Tilray Brands

Hedge funds and other institutional investors have recently modified their holdings of the stock. Tidal Investments LLC lifted its stake in shares of Tilray Brands by 15.0% in the 2nd quarter. Tidal Investments LLC now owns 28,971,835 shares of the company’s stock valued at $12,006,000 after acquiring an additional 3,776,410 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Tilray Brands by 281.0% during the 3rd quarter. Millennium Management LLC now owns 4,942,319 shares of the company’s stock valued at $8,550,000 after acquiring an additional 3,645,060 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Tilray Brands during the 3rd quarter worth $5,813,000. Ausdal Financial Partners Inc. acquired a new position in Tilray Brands in the 2nd quarter worth about $939,000. Finally, Swiss National Bank increased its holdings in Tilray Brands by 4.4% in the 3rd quarter. Swiss National Bank now owns 2,013,038 shares of the company’s stock worth $3,483,000 after purchasing an additional 84,900 shares in the last quarter. Institutional investors own 9.35% of the company’s stock.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.